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iomarkers in Acute Cardiac Disease
he Present and the Future
llan S. Jaffe, MD,* Luciano Babuin, MD,* Fred S. Apple, PHD†
ochester and Minneapolis, Minnesota
The use of biomarkers to aid diagnosis and treatment is increasing rapidly as genomics and
proteomics help us expand the number of markers we can use and as an improved
understanding of the pathophysiology of cardiac disease guides their use. However, as with all
rapidly expanding fields, there is the risk of excessive enthusiasm unless we are circumspect
about the data that guide the clinical use of these new tools. This review focuses first on how
to use troponin, which at present is the best validated of the new markers, and will hopefully
provide insight into how to use this biomarker more productively by distinguishing subsets of
patients and by providing an understanding of the meaning of elevations in various clinical
situations. The review then discusses the use as well as the knowledge gaps associated with
emerging biomarkers such as B-type natriuretic peptide and C-reactive protein, which are
increasingly moving toward more productive clinical use. Finally, it reflects on some of the
large number of markers that are still in development. (J Am Coll Cardiol 2006;48:1–11)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.056© 2006 by the American College of Cardiology Foundation
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tn improved understanding of pathophysiology and im-
rovements in the ability to identify potentially important
iomarkers via genomics and proteomics (1,2) has led to a
roliferation in the number of biomarkers available to
linicians. Many of these improve our understanding of
athophysiology (3,4). However, the bias in favor of positive
eports combined with the fact that analyses often focus on
rognostic value allows for the possibility of not capturing
he entire picture when evaluating a new analyte. In addi-
ion, there are concerns regarding the analysis of data
ublished about these markers, including the use of inap-
ropriately low cutoff concentrations for standard biomark-
rs such as cardiac troponin (cTn) and C-reactive protein
CRP), the use of insensitive analytical methods for analytes
sed for comparison or as covariates, the use of single
amples when serial samples would be most useful, the lack
f information relating the timing of patient presentation
nd sampling, the use of specimens without data showing
hat they have been appropriately preserved, and the tech-
ique of using one biomarker at a predetermined concen-
ration and then performing receiver-operating curve anal-
sis to determine the optimal level for the new biomarker
eing studied (5). At times, populations of patients are
dmixed to show that a given biomarker does well when
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ccepted February 16, 2006.ompared with another when the marker used as a compar-
tor would never be abnormal in some of the populations
ncluded. An example of how much difference these
ssues can induce is shown in Figure 1 from the FRISC
FRagmin and Fast Revascularization during InStability
n coronary artery disease) database (6). Note that even at
value 20 times the upper limit of normal (0.2 ng/ml) for
TnT, only 60% of the values with the less sensitive assay
ere detected. Rather than troponin identifying 139 of
he 154 patients who eventually died, the point of care
roponin I assay identified only 98. Thus, a new marker
ight look very different depending on which troponin
ssay was used as a comparator. These issues, if not
andled carefully, can exaggerate the importance of new
arkers. Many of the new biomarkers will overlap
ubstantially, and their use likely will not be synergistic
ut duplicative. It will take some time to sort out which
iomarkers are of clinical diagnostic and/or prognostic
alue. Accordingly, this review will: 1) define the use of
he present state-of-the-art biomarkers for the diagnosis
f patients with acute cardiovascular disease; 2) touch on
arkers of historical interest whose use should be dimin-
shing or eliminated; and 3) identify emerging markers,
nd 4) identify biomarkers in the developmental stage.
STABLISHED BIOMARKERS
Tn. There is one biomarker that has been established for
iagnosis (7,8) and that also provides robust prognostic
nformation (9–11) and that is cTn. The cTn biomarkers,
ssuming high-quality analytic methods, whether for cTnI
r cTnT, are highly specific and sensitive for cardiac injury
12). With the exception of renal dysfunction (see later
ext), cTnI and cTnT provide equivalent clinical
nformation.
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Cardiac Biomarkers: Present and Future July 4, 2006:1–11SSAY-RELATED ISSUES. The cTn are regulatory proteins
ith both cytosolic and structural pools. Best data suggest
hat they are released because of necrosis (7,8). Early release
s thought to be attributable to the cytosolic pool, and later
elease to the structural pool (7,8). There are now a
ultiplicity of assays for cTnI (13), which makes standard-
zation problematic (14). All have different analytical sensi-
ivities. It is essential for clinicians to understand whether
hey use a highly sensitive assay or one that lacks sensitivity
t the cutoff concentrations used for clinical decisions. The
nternational Federation for Clinical Chemistry has pro-
ided a comparison of analytical imprecision (sensitivity) for
TnI assays (13). There is substantial heterogeneity of assay
ensitivities (Fig. 2). Different assays measure different
pitopes and different fragments of cTnI. Thus, there are
ifferences in the responses of specific assays to the various
roponin forms (15), and assays probably detect slightly
ifferent groups of patients, depending on the nature and
iming of cTn release. A list of assays and their cut off values
s included in Table 1. Recent data suggest that a subset of
atients may have antibodies to parts of cTnI that can result
n occasional false-negative results (16). The heterogeneity
f assays is not a problem for cTnT because there is only one
ssay. There is a need to improve the rapidity with which
igure 1. The percentage of values for cardiac troponin (cTn)T collected fr
ith less sensitivity and precision. Any cTnT value 0.01 ng/ml is abnor
Abbreviations and Acronyms
ACS  acute coronary syndrome
BNP  B-type natriuretic peptide
CK  creatine kinase
CRP  C-reactive protein
cTn  cardiac troponin
ECG  electrocardiogram
ESRD  end-stage renal disease
PCI  percutaneous coronary interventionor cTnT, only 60% of the values with the less sensitive assay were detected. Thu
ied, the point-of-care assay identified only 98 patients. Reprinted, with permissay results are available. Clinicians expect values in 30 to
0 min, laboratorians in 60 min, whereas in reality results
re often available only after 100 min or more (17).
SE OF THE MARKER. The basic science substrate for use of
Tn has been elucidated elsewhere (12,18). For clinical use,
everal principles are important.
The cTn elevations begin 2 to 4 h after onset of
ymptoms (Fig. 3). With the use of precise highly sensitive
ssays and the use of the 99th percentile reference cutoff
ecommended, cTn provides all the information needed for
he evaluation of patients who present with possible acute
schemic heart disease. Other “rapidly increasing biomarkers”
ave little or no utility if this approach is used (Fig. 4) (19).
Elevations of cTn persist for days (cTn 5 to 10, cTnT 5
o 14). There are emerging data suggesting that re-
levations and an increasing pattern are the best way to
etermine whether a given event is acute or whether the
levation is one from a previous event or is chronic. This
oncept is important when there is an elevation in the initial
ample, when reinfarction is suspected (20), and in patients
ith end-stage renal disease (ESRD), who can have chronic
levations.
The number of patients identified with cTn in patients
ith possible acute ischemic heart disease depends on the
ubset of patients being evaluated. Patients with ST-
egment elevation infarction are different from those with
igh-risk acute coronary syndrome (ACS) presentations and
rom those who manifest moderate-risk and/or low-risk
resentations (21).
Because of the sensitivity of cTn, elevations are common
n patients with a large number of acute and chronic
ardiovascular diseases. It is up to the clinician to decide
hether the presentation is one of acute ischemia. If so,
levations can make the diagnosis of acute myocardial infarc-
ion, as defined by the European Society of Cardiology/
e FRISC II study associated with elevated values for a point-of-care assay
ote that even at a value 20 times the upper limit of normal (0.2 ng/ml)om th
mal. Ns, rather than troponin identifying 139 of the 154 patients who eventually
ssion, from James et al. (6). R-TnI  rapid troponin I.
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July 4, 2006:1–11 Cardiac Biomarkers: Present and Futuremerican College of Cardiology (7,8). If acute ischemia is
ot present, alternative etiologies should be sought and
ifferent diagnoses made. A partial listing of situations in
hich cTn can be elevated in the absence of acute ischemic
eart disease is included in Table 2.
atients with ST-segment elevation myocardial infarc-
ion. Patients with acute ST-segment elevation myocardial
nfarction do not need biomarker measurements before
herapy. Patients with elevated cTn on presentation have a
ower rate of coronary recanalization, whether with throm-
olysis (10) or direct percutaneous coronary intervention
PCI) (22) and an adverse short-term and long-term prog-
osis (23,24). Part of this effect is related to the fact that it
akes time for cTn to become elevated in the blood, and
able 1. Presently Available Assays for Cardiac Troponin and
ey Values
Assay LLD 99th Percentile ROC Cutoff
bbott ARCH 0.009 0.012 0.3
bbott i-STAT* 0.02 0.08 (WB) ND
ayer Centaur 0.02 0.1 1.0
eckman Accu 0.01 0.04 0.5
iosite Triage* 0.19 0.19 0.4
ade RxL 0.04 0.07 0.6–1.5
ade CS*† 0.03 0.07 0.6–1.5
PC Immulite 0.1 0.2 1.0
rthos Vitros 0.02 0.08 0.4
esponse* 0.03 0.03 ND
oche Elecsys (cTnT) 0.01 0.01 0.1
oche Reader* 0.05 0.05 0.1
osoh AIA 0.06 0.06 0.31–0.64
Point-of-care assay. †Cleared by the U.S. Food and Drug Administration as
igh-sensitivity assay, 2004.
99th  upper limit of normal and the ROC value equates cardiac troponin values
n general with creatine kinase-MB elevations; cTnT  cardiac troponin T; LLD 
igure 2. Sensitivity and precision of various cardiac troponin I (cTnI) assa
y the International Federation for Clinical Chemistry committee. (A to
etecting the lower values with reasonable precision. Reprinted, with permn
ower limit of detection; ND  not done; ROC  receiver-operating curve; WB 
hole blood.atients who come in late do less well than patients who
ome in early. However, even when one corrects for time of
nset, the same prognostic effect is found (25). In one study
f patients with inferior infarctions, stenting seemed to
mprove the prognosis of this group (26).
Infarct size can be estimated from the 72-h troponin
alue. The data are stronger for this approach with cTnT
han with cTnI (27,28). For cTnI, peak levels work better
29,30), but the data vary depending on whether or not
here has been acute reperfusion (29).
igh-risk patients with ACS. This group has been exten-
ively studied. Patients often are elderly, and have chest pain
t rest, transient electrocardiogram (ECG) changes, increas-
ng symptoms or signs of ischemia, evidence of hemody-
amic instability, and/or arrhythmias. They have a high
ncidence of elevated cTn when one uses the 99th percentile
eference range (31,32). They meet criteria for non–ST-
egment elevation myocardial infarction (7,8,12). The ele-
ated cTn defines a high-risk subset and provides guidance
n regard to therapy. Patients with elevated cTn have more
rocoagulant activity and an adverse coronary anatomy as
udged by the degree and extent of angiographic stenosis,
he Thrombolysis In Myocardial Infarction (TIMI) grade of
erfusion, and the complexity of the coronary lesions (33).
s such, these patients do better with the use of low-
olecular-weight heparin (34), IIb/IIIa anti-platelet agents
35), and an early invasive interventional strategy (36). Most
f the trials of IIb/IIIa agents were done before the routine
se of clopidogrel. Recent data suggest that these agents
ay be synergistic (37). Clopidogrel is the one agent that
ccrues benefit to patients whether or not cTn values are
levated (38). These more aggressive therapies not only are
rovided by measurements made by the manufacturers from pools provided
creasing concentrations of cTnI. Note that many assays are incapable of
n, from Panteghini et al. (13). CV  coefficient of variation.ys as pot beneficial but in some studies seem to even be detri-
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Cardiac Biomarkers: Present and Future July 4, 2006:1–11ental if applied to patients without cTn elevations. The
ne area where there is some question comes from the
ACTICS–TIMI-18 (Treat Angina with Aggrastat and
etermine Cost of Therapy with an Invasive or Conserva-
ive Strategy–Thrombolysis in Myocardial Infarction-18)
tudy, in which based on one admission sample for cTn, it
as claimed that female patients with elevations in B-type
atriuretic peptide (BNP) and/or CRP benefited from an
arly invasive strategy even if cTn were normal (39).
ndeterminate- and low-risk patients. This patient group is
ard to triage clinically. They may not have rest pain or
ngoing pain, may have normal ECGs, and depending on
he specifics, may be at intermediate or low risk. The
requency of elevated cTn is lower, nonetheless, these
igure 3. Time course of the appearance of various markers in th
oncentrations/activity curves for myoglobin and creatine kinase (CK) i
ith cardiac troponin some patients have a second peak in addition. Cigure 4. Sensitivity of cardiac troponin (cTn)I compared with myoglobin and c
se of the 10% coefficient of variation (0.1 ng/ml) were superior to the use of matients benefit optimally from triage with cTn. The most
obust trial was one by Hamm et al. (40) in 733 patients.
lmost every patient at short-term risk (30 days) was
dentified by elevations in cTn. Two caveats are important.
irst, cTn value had to have been obtained at least 6 h after
he onset of symptoms. This may be less necessary now with
ore sensitive assays. The second caveat is related to
ensitivity. Detectability was considered abnormal. We now
ave more sensitive assays, which should make for even
reater predictive accuracy. Even for patients at low risk, the
nding of an elevated cTn is prognostic. Some studies
howing this prognostic effect were not done with contem-
orary assays, which now allow for lower clinical cutoffs.
ne would suspect that the data would be even more
od after acute myocardial infarction (AMI). Shown are the time
ms, troponin after large and small infarctions, and CK-MB. Note that
coefficient of variation.e bloreatine kinase (CK)-MB for the detection of myocardial injury. Note the
yoglobin. Reprinted, with permission, from Eggers et al. (19).
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July 4, 2006:1–11 Cardiac Biomarkers: Present and Futurempressive with this approach. Nonetheless, in a cohort at
ow risk (a 5% to 7% incidence of acute myocardial infarc-
ion) whose ECGs are mostly normal, an elevated cTn is
ssociated with nearly a 90% frequency of coronary artery
isease by angiography (41). This was compared with a
requency of 23% in the group without elevations. It is likely
hat the additional patients who had angiographic disease
ay have been detected had the more sensitive cTn assays
nd low cutoffs been used. During 1-year follow-up, pa-
ients with elevated cTn values, two-thirds of whom had
able 2. Elevations of Troponin in the Absence of Overt
schemic Heart Disease
rauma (including contusion, ablation, pacing, implantable cardioverter-
defibrillator firings including atrial defibrillators, cardioversion,
endomyocardial biopsy, cardiac surgery, after interventional closure
of atrial septal defects)
ongestive heart failure—acute and chronic
ortic valve disease and hypertrophic obstructive cardiomyopathy with
significant left ventricular hypertrophy
ypertension
ypotension, often with arrhythmias
ostoperative noncardiac surgery patients who seem to do well
enal failure
ritically ill patients, especially with diabetes, respiratory failure
rug toxicity, e.g., adriamycin, 5-fluorouracil, herceptin, snake venoms
ypothyroidism
pical ballooning syndrome
oronary vasospasm
nflammatory diseases, e.g., myocarditis, e.g., Parvovirus B19, Kawasaki
disease, sarcoid, smallpox vaccination, or myocardial extension of
bacterial endocarditis
ost-percutaneous coronary intervention patients who seem to have no
complications
ulmonary embolism, severe pulmonary hypertension
epsis
urns, especially if total body surface area is 30%
nfiltrative diseases including amyloidosis, hemachromatosis, sarcoidosis,
and scleroderma
cute neurological disease, including cerebrovascular accident,
subarachnoid bleeds
habdomyolysis with cardiac injury
ransplant vasculopathy
ital exhaustionigure 5. Cardiac events after emergency department discharge based on leve
t al. (42).wo- or three-vessel disease, had an increased frequency of
vents. These data are similar to those from emergency
oom studies of patients who had “minor elevations” of cTn
Fig. 5) (42). Some degree of caution is necessary in all of
hese situations. A normal troponin value is not an impri-
atur against disease, especially if the assay in use is either
nsensitive or is used at a high cutoff value.
atients with chronic renal disease. The most common
ause of death in chronic renal failure is cardiovascular, and
oronary artery disease is common. The cTn values, espe-
ially with cTnT, are often abnormal (43,44). Initially, this
as presumed to be because cTnT was less tissue specific.
owever, extensive studies have now been done to show
hat this is not the case (45). Nonetheless, the frequent
TnT elevations (30% to 70% of ESRD patients compared
ith 5% in similar patients for cTnI) are problematic to
linicians (43,44). Several suggestions may be helpful.
In patients with an ACS, an elevated cTn, whether cTnI
r cTnT, should be treated as if renal failure (chronic or
cute) were not present (46). These patients are at increased
isk. Although all of the therapeutic caveats cannot be
pplied from all of the studies, many of which had only
imited numbers of patients with ESRD, it seems likely that
hese individuals also would benefit from an aggressive
ntithrombotic (47) and interventional approach (48).
For patients with ESRD who do not have ACS but have
levated cTn, several approaches are helpful; cTnT is now
pproved for prognostication in patients with ESRD. Thus,
aseline values can and should be obtained. The prognosis
all-cause death) of patients with ESRD and even minor
levations of cTnT is two to five times higher than those
ith undetectable values (49,50). C-reactive protein may
urther improve prognostication (50,51). Having a baseline
alue allows not only for prognostication but also for an
valuation of whether or not values are changing over time.
ncreasing values suggest an acute problem. In the absence
f increasing values, when a clinician does not find evidence
f an acute process known to cause elevations of cTn, one is
robably safe to consider these more chronic elevations.ls of cardiac troponin T. Reprinted, with permission, from Henrikson
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Cardiac Biomarkers: Present and Future July 4, 2006:1–11hese patients may require alteration in a variety of thera-
ies to improve their prognosis, but may not require acute
reatment. The putative mechanisms for these chronic
levations, which are invariably associated with pathologic
bnormalities at autopsy (52), include endothelial dysfunc-
ion, acute cardiac stretch, intradialysis hypotension and
ypertension, the use of iron sucrose, and left ventricular
ypertrophy. All are potentially benefited by altering the
requency of dialysis, the weight gain (fluid control), and the
lood pressure control. Given the high incidence of coro-
ary disease, some of these patients may have occult
nderlying coronary artery disease. Elevations of cTn in
atients with renal dysfunction but without ESRD are
ommon but likely attributable to the association of other
omorbidities and probably cannot be considered the same
s those seen in ESRD patients.
atients after PCI. Elevations of creatine kinase (CK)-MB
fter PCI presage adverse outcomes (53). The greater the
levation, the more adverse the prognosis. This has not
onsistently been the case with cTn. However, one would
uspect that it should be. There should, for each cTn assay,
e values that correlate with the CK-MB values. However,
his relationship may need to be confirmed with each assay
or each biomarker (CK-MB and troponin) in use locally.
ecent data suggest that many of the elevations observed
fter PCI both for cTn and CK-MB are presaged by
levations in cTn when sensitive assays and lower cutoff
alues are used (54). Thus, they could reflect ongoing
yocardial damage that has little to do with the procedure
tself or identify patients with a high likelihood or post-PCI
arker elevation. Patients who present with ACS who have
Tn elevations manifest worse angiographic disease and an
dverse prognosis. It may be that CK-MB not being
levated, because it is less sensitive compared with cTn, is
eductive to clinicians who believe it can be used as a
aseline; however, the effect may be the same. Thus, it is
nclear how to use either biomarker in patients who present
cutely or have an elevated cTn pre-procedure. If the
aseline cTn is normal pre-PCI and the patient has not
resented acutely, cTn and CK-MB values after PCI will likely
e informative about the procedure itself and elevations are
ssociated with early major adverse cardiac events (54).
atients after coronary artery bypass grafting. Patients
ho undergo cardiac surgery have some amount of cTn and
K-MB release (55). The higher the value, the worse the
ssociated injury, and high values presage subsequent events,
ncluding death. Elevations have been related to the surgical
pproach, the extent of cross-clamp and bypass time, the
ature of cardioplegia, and the nature of the procedure
valves and coronaries vs. coronary artery bypass grafting
lone). Magnetic resonance imaging studies suggest that
ost of the injury is subendocardial and apical (56). Graft
cclusion (57) as a cause of the injury does not seem to be
ommon. tatients who present with chest pain who have normal
ngiograms. One needs to be cautious in evaluating pa-
ients with elevated cTn even if an angiogram does not show
ignificant coronary disease. The coronary angiogram is not
erfect (58). In the TACTICS–TIMI-18 trial, individuals
ith an elevated cTn despite angiographically normal cor-
nary arteries had an adverse prognosis (59). This may
eflect the inadequacies of the angiogram or may be related
o the late angiography in some patients (60). In some data
ets, elevated cTn has been associated with asymmetric
esions that tend to be vasoactive (61). Thus, the finding of
ngiographically “normal” coronary arteries needs to be
nterpreted within the context of patient care. If the patient
oes not have an ACS but appears acutely ill, there are a
ariety of other etiologies, such as pulmonary embolism and
ongestive heart failure, in which even in the absence of
oronary artery disease elevated cTn can be observed (these
levations may be related to wall stress); patients who may
ave subendocardial ischemia/injury related to left ventric-
lar hypertrophy with diseases such as aortic stenosis or
ypertrophic cardiomyopathy or perhaps even severe hyper-
ension; myocarditis; and/or toxic insults such as seen with
epsis, in which tumor necrosis factor alpha and heat shock
rotein have been impugned as potential cardiac toxins.
OTENTIALLY OUTDATED MARKERS
K-MB. Creatine kinase-MB (18) is a cytosolic carrier
rotein for high-energy phosphates. As clinicians become
ore comfortable with cTn, it will have a diminishing role.
ome would argue that it still could be used to define infarct
iming or after PCI.
yoglobin and CK isoforms. Myoglobin, a ubiquitous
eme-related protein, and CK isoforms (18) have been used
ith the hope of shortening the time to a more definitive
iagnosis in patients with chest pain. They have been relied
n particularly for their negative predictive value. Recent
ata suggest that with modern contemporary sensitive assays
nd sensitive cutoffs for cTn, cTn can assume this role (19).
n the emergency room, where patients at low risk for
ardiovascular disease are still screened with cardiac bio-
arkers, it has been suggested that myoglobin may identify
dditional patients at risk. This is likely because of detection
f serious noncardiovascular disease (62).
MERGING MARKERS
or a marker to be useful, it needs to make a diagnosis or to
efine prognosis in such a way that it guides therapy. In this
egard, there are two emerging markers, CRP and the
atriuretic peptides BNP and NT-proBNP.
RP. ASSAY-RELATED ISSUES. C-reactive protein is an
cute-phase reactant protein made in the liver. Its most
roximate stimulator is interleukin 6. A specific receptor for
RP has recently been reported (63). There is controversy
egarding the variability of CRP levels (64,65). Some argue
hat in the absence of acute illness, including myocardial
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July 4, 2006:1–11 Cardiac Biomarkers: Present and Futurenjury, levels of CRP are stable. Others argue that levels
uctuate and vary by gender and ethnicity (66). If one has an
levation and is acutely ill or has evolving infarction, the test
hould be repeated at least 2 weeks later (64). Values above
0 mg/l are likely caused by acute disease (67). Values3 mg/l
re associated with higher risk, and values 1 mg/l are
ssociated with low risk (64). Those between 1 and 3 mg/l are
onsidered intermediate (64). Multiple assays exist for CRP
designated high-sensitive CRP or hsCRP), and most give
omparable results.
SE OF THE MARKER. Recent data from the PROVE-IT
Pravastatin or Atorvastatin Evaluation and Infection Ther-
py) trial (68), which are consistent with those from the
EVERSAL (Reversal of Atherosclerosis with Aggressive
ipid-lowering Therapy) trial (69,70), suggest that the
itration of statin therapy predicated on CRP values would
esult in fewer events and regression of atherosclerosis. They
robably explain why in prior studies an elevated CRP level
as found to be prognostic for late events after presentation
ith ACS (71). In those studies, the changes in prognosis
nd extent of disease associated with differences in CRP
ere not associated with the effects observed with low-
ensity lipoprotein lowering (Fig. 6) (68). Differences in
vents started early after presentation. It seems that using
RP values as early as 30 days after infarction to avoid the
ffects of myonecrosis on CRP may be a reasonable ap-
roach. These trials did not titrate therapy based on CRP,
hich make the data provocative and suggestive but not
efinitive. Elevations of CRP often are related to numerous
ther clinical issues, such as obesity, diabetes, estrogen
herapy, hypertension, smoking, etc. Thus, an argument
ould be made that one should attempt to control these risk
actors before resorting to pharmacology.
The use of CRP for primary prevention is more contro-
ersial. There are abundant data concerning its prognostic
fficacy, but limited data showing that interventions are of
enefit save a suggestion in regard to aspirin (72) and statins
73). Given the large numbers of patients at risk, it isigure 6. Synergistic prognostic value of C-reactive protein (CRP) and low-den
rom Ridker et al. (68). MI  myocardial infarction.ifficult to show the cost effectiveness of this approach.
ecent guidelines have suggested the use of CRP in patients
ho are at intermediate risk for coronary artery disease to
ssist in defining the level of aggression of risk factor
ntervention (74).
NP. ASSAY-RELATED ISSUES. B-type natriuretic peptide
s a 32-amino-acid counterregulatory peptide released in
esponse to cardiac stretch. It is synthesized as a pro peptide
nd then cleaved to the active moiety by a protease called
orin (75,76). There are multiple immunoassays (75,76). In
eneral, they have similar diagnostic cutoff values of 100
g/ml for congestive heart failure, because this has been the
alue developed in early diagnostic studies. Above and
elow that value, they correlate less well (76). In addition,
here is an immunoassay for NT-proBNP (75,76), which
etects the 76 amino acid carrier protein, which with the
ctive 32 amino acid compound is called proBNP. This
rotein is thought to be cleaved when BNP is secreted.
owever, it seems that some proBNP circulates, and it is
ikely that many assays detect it. In addition, for both of
hese analytes, women and older individuals have higher
alues (69) and obese individuals have lower values (77)
Fig. 7). Patients with renal failure often have substantially
igher values (78). This increase is more accentuated for
T-proBNP. Both BNP and NT-proBNP manifest sub-
tantial biological variability (79). If formal values are relied
n, values have to either double or half to be sure that a
real” change has occurred.
SE OF THE MARKER. The BNP and/or NT-proBNP val-
es are helpful for the detection of congestive heart failure in
atients in whom one is unsure of the cause of dyspnea (80).
his is not the same as advocating its routine use (81). For
NP, values 100 ng/l make heart failure unlikely with a
egative predictive value of 90%. If the value is 500, heart
ailure is highly likely with a positive predictive value of 90%
82). For NT-proBNP, levels 450 ng/l for patients 50
ears of age and900 ng/l for patients50 years of age are
ensitive and specific for heart failure (83). If the value issity lipoprotein (LDL) in PROVE-IT study. Reprinted, with permission,

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Cardiac Biomarkers: Present and Future July 4, 2006:1–11300 ng/l, heart failure is highly unlikely with a negative
redictive value of 99% (83). However, in the middle
anges, the predictive accuracy is less and that is likely
here many of the less typical patients’ values will reside.
atients with right-sided heart failure, sepsis, volume
verload, stroke, and left ventricular hypertrophy also
ave higher values. In patients with acute pulmonary
dema and acute mitral regurgitation, values may not be
levated initially (82).
There is prognostic value of BNP and NT-proBNP as
ell in patients with heart failure (84,85). Patients with
igher values on admission and/or discharge to hospital
enerally do worse. Those with marked reductions during
reatment do better. However, the percentage changes with
herapy are less than anticipated and often less than biolog-
cal variability, suggesting that the natriuretic peptide sys-
em may require some time to upregulate and downregulate
86). In addition, in critically ill heart failure patients, low
alues are predictive of an adverse survival (87).
The BNP and NT-proBNP do not go down nearly as
apidly in response to therapy as one would expect from the
hort (20 min for BNP and 2 h for NT-proBNP) half-lives
86). This may relate to the time needed for the system itself
o autoregulate.
In ACS patients, BNP and NT-proBNP elevations are
rognostic for death in all studies, but the data are not
onsistent for recurrent myocardial infarction. When one
as a conjoint end point such as death, one can be
onfounded in evaluating myocardial infarction, however.
ecause so many studies have used optimized cutoff
alues for their own data sets, there is no consensus on the
roper cutoff values. In addition, what actions should be
redicated on elevated values are unclear (88,89). The only
rial in which it seemed that there was therapeutic guidance
ssociated with elevated values was the TACTICS–
IMI-18 study, in which women with elevated BNP or
Figure 7. Effect of weight on B-type natriuretic peptide (BNP) levels. RRP values seemed to benefit from early PCI even if they iad normal cTn values (39). If a strategy to treat such
Tn-negative patients could be developed, this could
rove to be an important adjunct to the evaluation of
atients who present with ACS.
Higher BNP values identify patients with ACS who are
t higher risk, but what to do in response is unclear.
levated values also predict an adverse outcome in stroke,
bstructive sleep apnea, diabetes, left ventricular hypertro-
hy, and stable coronary artery disease.
Thus, the questions regarding what are the appropriate
utoffs in the varied situations in which BNP and NT-
roBNP might be used and what one does when one
xceeds those cutoffs is unclear. Until these issues are better
efined, enthusiasm for the routine use of BNP or NT-
roBNP will be blunted.
EVELOPING MARKERS
CD40 ligand. sCD40 (90) is a signaling protein that
eflects both inflammatory and platelet interactions with the
laque. Increased sCD40 ligand has been shown in patients
ith ACS. Moreover, articles have suggested that is has
rognostic significance in these patients. Several of the
tudies have used high cutoff values for cTn or insensitive
ssays. A multiplicity of analytic issues remain.
yeloperoxidase. Myeloperoxidase (90), a degranulation
roduct, comes from white cells. Elevations occur even
hen values are obtained from the coronary effluent drain-
ng a nonculprit coronary vessel. Systemic levels have been
aid to aid in prognostication in patients presenting to the
mergency department with chest pain, but comparisons
ave often used high cTn cutoff values or only the admission
roponin level. Recently, a commercial assay has been made
vailable.
schemia-modified albumin. Ischemia-modified al-
umin (90) has been touted as a way to detect ischemia even
ed, with permission, from Krauser et al. (77). BMI  body mass index.f necrosis is not present. The theory is that the metal
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July 4, 2006:1–11 Cardiac Biomarkers: Present and Futureinding site on the amino terminus of albumin is damaged
y ischemia. It is marketed for its “negative predictive
alue.” It has been difficult to validate ischemia-modified
lbumin because of the lack of a gold standard for ischemia.
n addition, the assay is cumbersome to use.
regnancy-associated plasma protein-A. A member of
he insulin-like growth factor family of proteins, pregnancy-
ssociated plasma protein-A (90) is thought to be released
hen neovascularization occurs and thus may be a marker of
ncipient plaque rupture. It does not correlate with any of
he presently available markers of cardiac injury. It has in
ome studies seemed to identify patients at risk for subse-
uent events. There is no available standardized assay.
holine. Choline (90) is a biomarker that is released when
hospholipids are cleaved, which suggests that perhaps it
ould be a marker of ischemia and/or necrosis. Several
tudies suggest that the marker might improve prognosti-
ation in patients with ACS, but high cutoff values for cTn
ave generally been used.
lacental growth factor. Placental growth factor (90) is a
ember of the vascular endothelial growth factor family
hat has been touted by some but not others to be prognostic
n patients with ACS. Some of the positive studies have not
sed appropriate cTn cutoff values. There is no standard
ssay for placental growth factor.
ystatin C. This biomarker is a low-molecular-weight
asic protein (13 kDa) that is freely filtered and metabolized
fter tubular reabsorption. It seems that it is less influenced
y age, gender, and muscle mass than serum creatinine.
here is a U.S. Food and Drug Administration-cleared
ssay that is analytically robust. Some studies suggest that it
s useful for prognostication in heart failure (91,92) and
CS (93), and that would make sense given that it is well
ccepted that renal function is a critical determinant of
rognosis. It seems that there is an influence of inflamma-
ion of the marker that may complicate its use.
atty acid binding protein. Fatty acid binding protein is
apidly released after infarction and thus has been touted as
n alternative to myoglobin. It has been reported to perform
etter (94), but it still lacks cardiac specificity. There are no
.S. Food and Drug Administration-approved assays.
onclusions. The present and future for cardiac biomark-
rs is exciting. In the near future, many of these biomarkers
ill provide important new insights into pathophysiology
nd aid in the diagnosis and management of cardiovascular
atients. We are likely to be able to multiplex assays,
ersonalizing biomarker strategies and providing large num-
ers of values quickly and cheaply. There is great enthusi-
sm for such a multimarker approach. However, before we
mplement such a strategy, we must overcome poorly done
et enthusiastic limited reports (5), so that what is eventu-
lly recommended will work optimally clinically. In the
nterim, to provide optimal clinical care, clinicians need to
earn more about the biomarkers that they rely on in current
linical practice, i.e., cTn, natriuretic peptides, and CRP,
oth analytically and clinically.cknowledgment
ecause of limitations to the number of citations in this
eview, we apologize to those whose work could not be cited
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